{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T12:19:10Z","timestamp":1758457150511,"version":"3.44.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Medical Association"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/j.jnma.2017.02.005","type":"journal-article","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T21:47:42Z","timestamp":1489873662000},"page":"172-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT"],"prefix":"10.1016","volume":"109","author":[{"given":"L. Julian","family":"Haywood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry R.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda B.","family":"Piller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Cushman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles E.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara M.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alokananda","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsayed Z.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Jackson T.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jnma.2017.02.005_bib1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJM198204293061703","article-title":"Epidemiologic features of chronic atrial fibrillation: the Framingham Study","volume":"306","author":"Kannel","year":"1982","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.jnma.2017.02.005_bib2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","article-title":"Independent risk factors for atrial fibrillation in a population-based cohort","volume":"271","author":"Benjamin","year":"1994","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jnma.2017.02.005_bib3","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/01.CIR.96.7.2455","article-title":"Incidence of and risk factors for atrial fibrillation in older adults","volume":"96","author":"Psaty","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jnma.2017.02.005_bib4","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults. National implications of rhythm management and stroke prevention; the Anticoagulation and Risk Factor in Atrial Fibrillation (ATRIA) study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jnma.2017.02.005_bib5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIR.0b013e318224b037","article-title":"American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association","volume":"124","author":"Estes","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jnma.2017.02.005_bib6","first-page":"342","article-title":"Rationale and design for the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"9","author":"Davis","year":"1996","journal-title":"Hypertens"},{"issue":"22","key":"10.1016\/j.jnma.2017.02.005_bib7","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.jacc.2009.08.020","article-title":"Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial)","volume":"54","author":"Haywood","year":"2009","journal-title":"JACC"},{"issue":"6","key":"10.1016\/j.jnma.2017.02.005_bib8","first-page":"377","article-title":"Characteristics and lipid distribution of a large high-risk hypertensive population. The lipid-lowering component of the ALLHAT","volume":"5","author":"Papademetriou","year":"2003","journal-title":"J\u00a0Clin Invest"},{"issue":"23","key":"10.1016\/j.jnma.2017.02.005_bib9","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes of high-risk hypertension patients randomized in angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jnma.2017.02.005_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1751-7176.2011.00568.x","article-title":"Mortality and morbidity during and after the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial","volume":"14","author":"Cushman","year":"2012","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jnma.2017.02.005_bib11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/01.HYP.0000052830.02773.E4","article-title":"Atrial fibrillation in hypertension predictors and outcome","volume":"41","author":"Verdecchia","year":"2003","journal-title":"Hypertens"},{"key":"10.1016\/j.jnma.2017.02.005_bib12","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/eurheartj\/ehi694","article-title":"Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades","volume":"27","author":"Miyasaka","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jnma.2017.02.005_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0002-8703(00)90095-4","article-title":"Effects of amlodipine on exercise tolerance quality of life and left ventricular function","volume":"139","author":"Udelson","year":"2000","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.jnma.2017.02.005_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/FJC.0b013e318160b42a","article-title":"Comparative evaluation of effect of valsartan\/amlodipine and atenolol\/amlodipine combinations on atrial fibrillation","volume":"51","author":"Fogari","year":"2008","journal-title":"J\u00a0Cardiovasc Pharmcol"},{"issue":"7","key":"10.1016\/j.jnma.2017.02.005_bib15","first-page":"27","article-title":"Effect of calcium antagonists verapamil and amlodipine on the risk of development of atrial fibrillation after coronary artery bypass grafting","volume":"43","author":"Popov","year":"2003","journal-title":"Kardiologiia"},{"issue":"1","key":"10.1016\/j.jnma.2017.02.005_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejim.2009.05.001","article-title":"Agents with antialdosterone properties should be the preferred diuretics for reducing hypertension related atrial fibrillation","volume":"21","author":"Jolobe","year":"2010","journal-title":"Eur J Intern Med"},{"issue":"9","key":"10.1016\/j.jnma.2017.02.005_bib17","doi-asserted-by":"crossref","first-page":"l022","DOI":"10.1136\/hrt.2003.023069","article-title":"Atrial fibrillation after\u00a0radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors. angiotensin II receptor blockers and diuretics","volume":"90","author":"Ann\u00e9","year":"2004","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.jnma.2017.02.005_bib18","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/archinternmed.2010.427","article-title":"Antihypertensive treatment and development of heart failure in hypertension","volume":"171","author":"Sciarretta","year":"2011","journal-title":"Arch Inter Med"},{"key":"10.1016\/j.jnma.2017.02.005_bib19","article-title":"Effect of statins on atrial fibrillation, collaboration meta-analysis on published and unpublished evidence from randomized controlled trials","volume":"343","author":"Rahimi","year":"2011","journal-title":"BMI"},{"issue":"3","key":"10.1016\/j.jnma.2017.02.005_bib20","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijcard.2012.08.056","article-title":"The preventive effect of statin therapy on new onset of recurrent atrial fibrillation in patients not undergoing invasive cardiac intervention. A systemic review and meta-analysis","volume":"167","author":"Bang","year":"2013","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.jnma.2017.02.005_bib21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0735-1097(00)01107-4","article-title":"Epidemiology and natural history of atrial fibrillation: clinical implications","volume":"37","author":"Chugh","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jnma.2017.02.005_bib22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jacc.2004.06.080","article-title":"Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study","volume":"45","author":"Wachtell","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jnma.2017.02.005_bib23","first-page":"107","article-title":"Atrial\u00a0fibrillation and the risk of myocardial infarction","volume":"174","author":"Soliman","year":"2014","journal-title":"JAMA\u00a0Intern\u00a0Med"},{"issue":"11","key":"10.1016\/j.jnma.2017.02.005_bib24","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.hrthm.2014.08.003","article-title":"Acute myocardial infarction in patients with atrial fibrillation with a CHA2DS2-VASc score of 0 or 1: a nationwide cohort study","volume":"11","author":"Chao","year":"2014","journal-title":"Heart Rhythm"},{"issue":"3","key":"10.1016\/j.jnma.2017.02.005_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jchf.2013.12.006","article-title":"The association between atrial fibrillation and sudden cardiac death: the relevance of heart failure","volume":"2","author":"Reinier","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jnma.2017.02.005_bib26","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCULATIONAHA.110.009035","article-title":"Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study","volume":"123","author":"Huxley","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jnma.2017.02.005_bib27","first-page":"279","article-title":"Evaluating the atrial myopathy underlying atrial fibrillation: identifying the arrhythmogenic and thrombogenic substrate","volume":"4","author":"Goldberger","year":"2015","journal-title":"Circulation"}],"container-title":["Journal of the National Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0027968416301535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0027968416301535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:15:58Z","timestamp":1758435358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0027968416301535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"alternative-id":["S0027968416301535"],"URL":"https:\/\/doi.org\/10.1016\/j.jnma.2017.02.005","relation":{},"ISSN":["0027-9684"],"issn-type":[{"type":"print","value":"0027-9684"}],"subject":[],"published":{"date-parts":[[2017]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jnma.2017.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the National Medical Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}